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Abstract
Altered expression of a number of genes has been correlated to biological ageing
in humans. The biological age predicted from gene expression levels is known
as transcriptomic age. This differs from chronological age which is measured
as the time that an individual has lived since their date of birth. Transcrip-
tomic age can be older or younger than an individual’s chronological age. At
present, studies have focused on using transcriptomic data to predict transcrip-
tomic age. However, this approach largely does not consider the effect that genes
have on the metabolic network and therefore on the observable cellular pheno-
type. This research takes the current understanding of transcriptomic ageing a
step further by generating and investigating genome-scale metabolic models of
ageing, using machine learning methods and a multi-omic approach based on
constraint-based modelling. We combine these models with a transcriptomic age
predictor and gene expression data from CD4 T-Cells from human peripheral
blood mononuclear cells in healthy individuals. We show that metabolic models
augmented with transcriptomics data of ageing can generate greater metabolic
insights into the differences between chronological and transcriptomic age. Com-
pared to standard transcriptomic-only approaches, our method provides a more
comprehensive analysis of transcriptomic ageing and paves the way for a multi-
omic understanding of ageing mechanisms in human cells.
Introduction
Ageing is associated with phenotypes such as wrinkles, greying hair, hair loss
and frailty as well as diseases such as diabetes, osteoporosis and cardiovascular
disease. Underlying these characteristics of ageing are age-related changes to
our metabolic processes [1]. Changes to mitochondrial function, which is vital
for energy metabolism and homeostasis, have been linked to the ageing process
[2, 3]. Metabolic dysregulation leads to the build-up of fat stores in the abdominal
cavity [4]. This type of fat is called visceral fat. Higher visceral fat levels mean
a greater risk of insulin resistance, type 2 diabetes, cardiovascular disease and
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Fig. 1. Multi-omic ageing pipeline. We use the chronological data and correspond-
ing predictors to obtain the effect of both types of ageing on the transcriptomic layer.
We then combine the latter with the functional biological network data determined by
the metabolism and multi-omic model to obtain the multi-omic ageing map.
cancer [5–8]. However, a recent study by Chee et al. [9] suggests that some age-
related metabolic changes may not be inevitable but rather due to lifestyle. A
group of young (mean age 21.5) and older (mean age 69.7) participants who
were matched for physical activity levels and body composition were found to
have no significant difference in insulin resistance and lipid accumulation in their
muscles.
The term ’inflammaging’ was proposed by Franceschi et al. [10] to describe
the imbalance between inflammatory and anti-inflammatory networks which con-
tribute to the chronic diseases of ageing. The immune response declines dramat-
ically with ageing leading to increased frailty e.g. susceptibility to pathogens
such as influenza [11]. CD4 cells have recently been shown to be linked to the
ageing process. A study comparing gene expression from the same CD4 cells in
newborns, middle-aged and long-lived participants found significant expression
changes in the transcriptomes across the age groups [12]. The action of CD4
cells is impaired with age which contributes to the deterioration of the immune
response [13, 14].
Although genes are often regarded as the main players in deciding cell be-
haviour, it is difficult to predict how they affect the phenotype. Metabolic models
can therefore be used to predict the metabotype of a cell, and provide a close-to-
phenotype prediction of cell behaviour and fate. Furthermore, metabolic models
can be constrained using gene expression data [15].
The idea of this paper is that modelling how the gene expression alter-
ations change metabolic processes provides greater understanding of the age-
ing process and a more accurate prediction of biological age. This data can
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then be used to investigate how adding the metabolic information alters and im-
proves transcriptomics-only classifications of patients. Using transcriptomic data
from patients, we here generate patient-specific genome-scale metabolic models.
We then investigate such models in the context of ageing, therefore obtaining
metabolic ageing biomarkers. More specifically, the gene expression data from
CD4 cells is mapped to both the chronological age and the transcriptomic age
of the individuals in the cohort. This provided us with a baseline of the current
understanding of transcriptomic ageing in the transcriptomic layer, and allowed
us to investigate the metabolic processes that contribute to both chronological
and transcriptomic ageing.
Methods
Transcriptomic age predictor
Throughout our pipeline, we use a meta-analysis of CD4 T-Cell gene expression
from human peripheral blood mononuclear cells isolated from healthy individuals
in the Boston area. The CD4 cell gene expression data was profiled on Affymetrix
Human Gene 1.0 ST microarrays [16]. The raw data is accessible through GEO
accession number GSE56033. The dataset contains 499 individual patients. Using
1497 age-associated genes, i.e. those found to be differentially expressed with
chronological age, the effect size of each individual age-associated gene expression
level on chronological age was then calculated [17]. The sum of the effect sizes
of the age-associated genes on chronological age was used to calculate a general
transcriptomic predictor Z, defined as a linear combination:
Z =
∑
i
bixi, (1)
where xi is the gene expression level of the ith probe, and bi is the effect size for
the ith probe.
Starting from these predictors, we calculated the transcriptomic age of each
individual. To this end, the general transcriptomic predictor was scaled using
the mean and standard deviation of the chronological age and the mean and
standard deviation of the general predictor [17]. The transcriptomic age of an
individual is:
SZ = µage + (Z − µz)σage
σz
, (2)
where µage and σage are the mean and the standard deviation of the chronological
age, while µz and σz are the mean and the standard deviation of the predictor
Z.
Using (2), we calculated the transcriptomic ages for the 499 individuals. The
chronological data was included for each sample. The data was normalised using
RMA (Robust Multi-array Average) [18] followed by dividing the gene expression
values by the mean value for each probe. The effect size bi is defined on a gene
by gene basis. In cases where a probe represented more than one gene the effect
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sizes for those genes were averaged to give an on overall average effect size for
that probe.
To progress to a multi-omic understanding of transcriptomic ageing we used
a constraint-based model of the CD4 cell [19] augmented with transcriptomics
through METRADE [20]. This enabled us to create personalised metabolic mod-
els of the samples within the cohort. We then mapped the metabolic flux rate
to the chronological age of the individuals within the cohort and repeated this
pipeline using metabolic flux rate and transcriptomic age.
Constraint-based modelling
Given the matrix S of all known metabolic biochemical reactions and their sto-
ichiometry, and given the vector v of flux rates in a given growth condition [21],
constraint-based modelling and flux balance analysis (FBA) allow the prediction
of the distribution of flux rates in a given condition. The metabolic network is
solved by maximising a cellular objective (usually the biomass), with constraints
deriving from the steady-state condition Sv = 0 and additional constraints vmin
and vmax on lower bound and upper bounds of v.
Using METRADE [20] coupled with the transcriptomic data from each pa-
tient, we modify the upper- and lower- limits of reactions as a function of the
expression levels of genes involved in the reaction. For each patient, to predict
the cellular flux distribution when multiple objectives have to be taken into
account, we use the following bilevel linear program:
max gᵀv
such that max fᵀv, Sv = 0,
vminϕ(Θ) ≤ v ≤ vmaxϕ(Θ).
(3)
The vectors f and g are weights to select (or combine) the objectives to be
maximised from the vector v. The vector Θ converts the gene expression values
into coefficients for the bounds of reactions activated by those genes. This is
achieved through the function ϕ, which acts on Θ, the expression of a biochemical
reaction, is defined from the patient-specific expression levels of its genes, with
a rule depending on the type of enzyme (single gene, isozyme, or enzymatic
complex).
Cluster analysis
In order to compare the transcriptomic and metabolomic landscapes of ageing,
Agglomerative Hierarchical Clustering (AHC) was used to cluster both the tran-
scriptomic and fluxomic data. The transcriptomic data was RMA normalised fol-
lowed by dividing the gene expression values by the mean value for each probe
prior to clustering. AHC requires the distance between every pair of objects
in the dataset to be calculated prior to being able link objects together into
an hierarchical cluster tree based on proximity. AHC dissimilarity testing was
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carried out to find the distance and linkage combination that gave the high-
est Cophenetic Correlation Coefficient (CHC). For the transcriptomic data, the
linkage method that performed best was Average followed by Weighted, Com-
plete, Ward then Single. Further testing showed that Euclidean distance and
Average linkage gave the best CHC of 0.67. For the fluxomic data the best per-
forming linkage method was Average followed by Single, Weighted, Ward then
Complete. The highest CHC of 0.54 was obtained using Average linkage and
Squared Euclidean distance.
The average linkage method used the Unweighted Pair-Group Method with
Arithmetic Mean (UPGMA) [22] algorithm. UPGMA joins the pair of objects
with the smallest distance, then calculates the average between this pair and all
the other objects in the dataset, and repeats this cycle until all data has been
grouped into one cluster. The distance is computed as:
D(ij),k =
(
ni
ni + nj
)
Dik +
(
ni
ni + nj
)
Djk, (4)
where Dij is group (ij) which has n(ij) = ni + nj members and k is a new
cluster.
Results
In order to determine the optimal number of natural clusters the pairwise dis-
tance data for both the transcriptomic and fluxomic data were visualised using
scatter plots (Figure 2). The most distinct categorisation occurred at four clus-
ters for transcriptomic data. Figure 2 clearly shows the majority of the transcrip-
tomic data forming two large clusters. For the fluxomic data the most distinct
categorisation occurred at eight clusters. Figure 2 shows the fluxomic data falling
into four main clusters, though less distinct than the transcriptomic data.
Having determined the optimal number of natural clusters for both transcrip-
tomic and fluxomic data the data was further analysed to determine whether the
natural clusters correlated with chronological age, transcriptomic age, or both.
This analysis builds on recent research which has shown a correlation between
CD4 cells and ageing [23]. Scatter plots of transcriptomic age against cluster
number were produced for both transcriptomic and fluxomic data. These plots
were annotated by chronological age using both colour and size. The results of
the clustering with age are displayed in Figure 3 for the transcriptomic data and
for the fluxomic data.
From Figure 3 it can be seen that although the transcriptomic data formed
into two distinct clusters there is very little differentiation in chronological age
between the two clusters. There is, however, some differentiation in the transcrip-
tomic age with cluster one containing most of the older patients (approximately
38 and over) and cluster two containing most of the younger patients (approxi-
mately 29 and under). These results support the assertion that gene expression
levels are related more to biological ageing than chronological ageing. However,
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Fig. 2. The AHC pairwise distance matrix data. The pairwise distance plots
were obtained after multidimensional scaling. (Top) The top scatter plot shows the
pairwise Euclidean distance matrix for the transcriptomic data when classified into
four clusters. Here we can see the majority of the data has formed into two distinct
clusters. (Bottom) The bottom scatter plot shows the pairwise Squared Euclidean
distance matrix for the fluxomic data when classified into eight clusters. The fluxomic
data shows a more complex picture with most of the data forming into four less distinct
clusters.
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Fig. 3. AHC clustering of transcriptomic and fluxomic data with transcrip-
tomic age annotated by chronological age. Chronological age is annotated using
both colour and size. (Top) The top scatter plot shows clustering of the transcriptomic
dataset. Cluster 1 and cluster 2 show some differentiation with transcriptomic age.
Cluster 1 contains a greater proportion of the older transcriptomic age range from ap-
proximately 38 years and older. Cluster 2 contains most of the patients under 29. Very
little differentiation can be seen according to chronological age. (Bottom) The bottom
scatter plot shows clustering of fluxomic data. Although most of the data is captured
in cluster 2, the fluxomic data shows some differentiation in both chronological and
transcriptomic age. For chronological age, cluster 3 captures mainly the 20-30 year age
range while cluster 5 appears to capture 30s to early 40s. For transcriptomic age, clus-
ter 3 captures 30s to mid 40s, cluster 5 captures 20s, late 30s and early 40s and cluster
6 captures early 30s and late 40s. Cluster 7 and 8 contain small subsets of patients in
the 20s and 30s respectively.
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the clustering has a low level of granularity with not much differentiation be-
tween age groups.
The fluxomic data in Figure 3 shows a more complicated picture. Most of the
data is contained in cluster two for both chronological and transcriptomic age.
There is some differentiation in chronological ageing with cluster three appearing
to capture mainly the 20-30 year age range and cluster five appearing to capture
30s to early 40s. There is also some differentiation in transcriptomic ageing
with cluster 3 capturing 30s to mid 40s, cluster five capturing late 30s and
early 40s and cluster six capturing early 30s and late 40s. The last two clusters
(seven and eight) contain non-overlapping subsets of patients in their 20s and 30s
respectively. This appears to show greater differentiation than the transcriptomic
data between both chronological and transcriptomic ageing which suggests that
further analysis could provide deeper insights into the metabolism of ageing.
The standard deviation was calculated to determine the within cluster vari-
ation of the chronological ages. Fluxomic data had the lowest average standard
deviation overall of 5.6776 for 4 clusters. The lowest average standard deviation
for the transcriptomic data was 6.0498 for 2 clusters. To determine the between
cluster variation an F-test was performed. The fluxomic results for 4 clusters
showed the difference of standard deviation between cluster 7 and the other
clusters was statistically significant (p < 0.05). No significant results were found
for transcriptomic data. These results show that, for this dataset, clustering
by fluxomic improves the clustering by transcriptomics. Using a multi-variate
method such as Principal Component Analysis for further investigation could
allow the identification of the principal metabolic fluxes involved in different age
groups and hence in the ageing process.
Conclusion
As with many diseases and health conditions, transcriptomics only is unlikely
to reveal the full picture of ageing [24–26]. Multi-omic stoichiometric modelling
can be used to predict the effects of gene expression on the metabolism and
vice versa. More specifically, where a set of genes are known to be involved in a
disease, genome-scale models can be integrated with transcriptomic data. Using
a multi-omic model of ageing, we here achieve a greater understanding of the
mechanisms of the disease by modelling the effect of altered gene expression on
the metabolism of an organism (Figure 1).
Interestingly, we are able to obtain a metabolomic network of patients, as
opposed to the transcriptomic-only network commonly obtained from gene ex-
pression data. We applied agglomerative hierarchical clustering to visualize func-
tional mapping of local enrichment of the metabolic flux rate response to the
chronological and transcriptomic ageing processes. We report that the correla-
tion between the chronological age and transcriptomic age shows the relationship
between the transcriptomic layer and the metabolomic layer.
Future analyses, such as principal component analysis of the multi-omic data
will enable us to show which metabolic pathways correlate with ageing. We
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will therefore be able to identify biomarkers that, taken together, can define
a metabolomic age predictor. This can, for example, allow the classification of
patients into different phenotypes depending on the metabolic presentation of
the disease. Our model could also be used as a diagnostic/prognostic tool e.g.
for early chronological ageing.
We finally showed that, using machine learning approaches, we can classify
patients according to their metabolic phenotype of ageing by detecting global
similarity between patients across multiple omics. As a result, we reach a multi-
omic and genome-scale viewpoint that significantly extends the state-of-the-art,
but transcriptomic-only, understanding of ageing.
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